Ercros Total Liabilities
Ercros total liabilities. Based on the latest financial reports, Ercros (ECR) has total liabilities worth €485.35 Million EUR (≈ $567.42 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ECR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ercros (2000–2025)
Total liabilities of Ercros from 2000 to 2025. This chart illustrates how Ercros's total liabilities have evolved over time, based on quarterly financial data. Explore ECR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Ercros Competitors by Total Liabilities
The table below lists competitors of Ercros ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
China | CN¥211.52 Million |
|
Pollard Banknote Limited
TO:PBL
|
Canada | CA$315.29 Million |
|
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
SHG:600671
|
China | CN¥353.14 Million |
|
Hubei Guochuang Hi-tech Material Co Ltd
SHE:002377
|
China | CN¥1.05 Billion |
|
Build-A-Bear Workshop Inc
NYSE:BBW
|
USA | $175.10 Million |
|
AnHui Annada Titanium Industry Co Ltd
SHE:002136
|
China | CN¥902.05 Million |
|
Wave Cyber Shanghai Co Ltd
SHG:688718
|
China | CN¥141.72 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Ercros's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ercros balance sheet assets.
Liquidity & Leverage Metrics
Ercros Total Liabilities Ratios Explained
Ercros total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ercros's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ercros (2000–2025)
The table below shows the annual total liabilities of Ercros from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €396.07 Million ≈ $463.05 Million |
+10.62% |
| 2024-12-31 | €358.03 Million ≈ $418.58 Million |
+11.82% |
| 2023-12-31 | €320.20 Million ≈ $374.35 Million |
-17.01% |
| 2022-12-31 | €385.84 Million ≈ $451.09 Million |
+1.98% |
| 2021-12-31 | €378.34 Million ≈ $442.32 Million |
+23.64% |
| 2020-12-31 | €306.00 Million ≈ $357.75 Million |
-16.01% |
| 2019-12-31 | €364.33 Million ≈ $425.94 Million |
+9.11% |
| 2018-12-31 | €333.90 Million ≈ $390.37 Million |
-5.06% |
| 2017-12-31 | €351.68 Million ≈ $411.15 Million |
+3.33% |
| 2016-12-31 | €340.35 Million ≈ $397.90 Million |
+1.35% |
| 2015-12-31 | €335.80 Million ≈ $392.59 Million |
-4.75% |
| 2014-12-31 | €352.53 Million ≈ $412.14 Million |
-10.09% |
| 2013-12-31 | €392.08 Million ≈ $458.38 Million |
-9.10% |
| 2012-12-31 | €431.31 Million ≈ $504.25 Million |
+3.07% |
| 2011-12-31 | €418.45 Million ≈ $489.21 Million |
-3.69% |
| 2010-12-31 | €434.46 Million ≈ $507.93 Million |
-0.06% |
| 2009-12-31 | €434.72 Million ≈ $508.23 Million |
-3.36% |
| 2008-12-31 | €449.83 Million ≈ $525.90 Million |
-7.42% |
| 2007-12-31 | €485.89 Million ≈ $568.06 Million |
-24.76% |
| 2006-12-31 | €645.81 Million ≈ $755.02 Million |
+27.14% |
| 2005-12-31 | €507.94 Million ≈ $593.84 Million |
+90.38% |
| 2004-12-31 | €266.81 Million ≈ $311.93 Million |
+18.19% |
| 2003-12-31 | €225.75 Million ≈ $263.93 Million |
+16.04% |
| 2002-12-31 | €194.55 Million ≈ $227.45 Million |
-2.32% |
| 2001-12-31 | €199.17 Million ≈ $232.85 Million |
-99.44% |
| 2000-12-31 | €35.26 Billion ≈ $41.22 Billion |
-- |
About Ercros
Ercros, S.A., together with its subsidiaries, manufactures and sells chemical and pharmaceutical products in Spain and internationally. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmaceuticals. The company offers ammonia, caustic soda and potash, chlorine chloroisocyanurates, dichloroethane, ercrosbio, hydrochloric acid, hydrogen peroxide, polyvinyl ch… Read more